Genomma Lab Internacional, S.A.B. DE C.V. (Mexico)

Genomma Lab Internacional, S.A.B. de C.V., founded in 1996 and headquartered in Mexico City, is a leading Mexican multinational in the pharmaceutical and personal care products sector. The company develops, manufactures, markets, and distributes a wide range of over-the-counter (OTC) medicines, generic drugs, and personal care products across Mexico, Latin America, and the United States. Its product portfolio addresses categories such as anti-acne, hair loss, muscle pain, antifungals, gastrointestinal health, stress relief, skincare, and infant nutrition. Genomma Lab’s most recognized brands include Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, SilkaMedic, Nikzon, Lomecan V, and Shot B, among others. The company is publicly traded on the Mexican Stock Exchange (BMV: LABB) and the OTC Markets (GNMLF). It is led by Juan Marco Sparvieri (CEO) and Rodrigo Herrera Aspra, its founder and Chairman of the Board. Genomma Lab employs over 1,600 people and operates through subsidiaries in Mexico, the U.S., Peru, Chile, Ecuador, and Honduras. Historically, Genomma Lab began as a marketing-driven pharmaceutical company and evolved into a vertically integrated manufacturer with a strong focus on sustainability, innovation, and global expansion. It has consistently invested in R&D, digital transformation, and ESG initiatives, positioning itself as a benchmark in Latin American healthcare and wellness markets.